[1] Sarkar M, Srinivasa, Madabhavi I,et al. Tuberculosis associated chronic obstructive pulmonary disease. Clin Respir J,2017,11(3):285-295.
[2] World Health Organization.Globe tuberculosis report,2015.Geneva:World Health Organization,2015:14.
[3]Allwood BW,Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration, 2013, 86(1): 76–85.
[4] Salvadó M, Garcia-Vidal C, Vázquez P, et al. Mortality of Tuberculosis in very old people. J Am Geriatr Soc, 2010, 58(1):18-22.
[5] Huang SJ, Wang XH, Liu ZD, et al.Vitmine D deficiency and the risk of tuberclosis:a meta-analysis. Drug Des Devel Ther,2016,11:91-102.
[6] Allwood BW, Gillespie R, Galperin-Aizenberg M, et al. Obstructive pulmonary disease in patients with previous tuberculosis: Pathophysiology of a community-based cohort. S Afr Med J, 2017, 107(5):440-445.
[7]O'Toole RF, Shukla SD, Walters EH.TB meets COPD: An emerging global co-morbidity in human lung disease. Tuberculosis (Edinb). 2015,95(6):659-663.
[8] Chakrabarti B, Calverley PM, Davies PD. Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis,2007,2(3):263–272.
[9]陈会兰.老年慢性阻塞性肺疾病合并肺结核21例误诊分析.中国全科医学,2006,9(22):1884.
[10]方兰君,潘绮丽,江勇,等.老年肺结核107例临床分析.实用医学杂志,2006,22(23):2771-2772.
[11]李勇扑.老年肺下叶结核18例误诊分析.临床误诊误治,2004,17(12):851-852.
[12]李琦,姜晓颖,梁建琴,等.含左氧氟沙星或莫西沙星方案治疗耐多药肺结核的疗效分析.中国防痨杂志,2016,38(6):436-442.
[13]Park JH, Na JO, Kim EK, et al. The prognosis of respiratory failure in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis,2001,5(10):963-967.
[14] Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med,2003,97(11):1237-1242.
[15]Kim SJ, Lee J, Park YS, et al. Effect of airflow limitation on acute exacerbations in patients with destroyed lungs by tuberculosis. J Korean Med Sci, 2015,30(6):737-742.
[16]刘晔,代冰,苏佳,等.家庭无创通气对重度慢性阻塞性肺疾病稳定期患者疗效的荟萃分析.中华结核和呼吸杂志,2017, 40(5) :354-362.
[17] 中国防痨协会临床专业委员会.结核病临床诊治进展年度报告(2012年)..中国防痨杂志,2013,35(6):
405-426.
[18] Hale BG , Albrecht RA , García-Sastre A . Innate immune evasion strategies of in?uenza viruses . Future Microbiol ,2010 , 5 ( 1 ): 23-41 .
[19] Sin DD , Tashkin D , Zhang X , et al . Budesonide and the risk of pneumonia: a meta-analysis of individual patient data . Lancet,2009,374 ( 9691 ): 712-719 .
[20] Singh S , Loke YK . Drug safety assessment in clinical trials: methodological challenges and opportunities . Trials,2012,13 : 138 .
[21] Kesten S , Plautz M , Piquette CA ,et al. Premature discontinuation of patients: a potential bias in COPD clinical trials . Eur Respir J,2007,30 ( 5 ): 898-906 .
[22] 王睿荣,巨永利,王周勋,等.慢性阻塞性肺疾病合并肺结核 51 例临床分析.中国呼吸与危重监护杂志.,2012,11(5):494-497.
[23] 厍启录,孟伟民.COPD合并肺结核、肺心病的治疗体会.中国医药指南,2014,12(29):384-385.
[24] Iovino F , Brouwer MC , van de Beek D , et al . Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease . Cell Microbiol,2013,15 ( 6 ): 870-881.
[25] American Thoracic Society&Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med, 2000,161(4 Pt 2):S221-S247 .
[26]McCarthy B,Casey D,Devane D,et al.Pulmonary rehabilitation for chronic obstructive pulmonary disease.Cochrane Database Syst Rev,2015,23(2):CD003793. |